Dabigatran significantly raises the risk of major bleeding and gastrointestinal bleeding across all subgroups of patients with atrial fibrillation, and particularly in African Americans and patients...
VIENNA – Vedolizumab, a second-line biologic for treating patients who have ulcerative colitis or Crohn’s disease and don’t respond to an anti-tumor necrosis factor drug, is gaining traction...
VIENNA – Fourteen days of daily treatment with mongersen, an oral, antisense oligonucleotide, safely produced remissions in two-thirds of patients with Crohn’s disease in a phase II study with a...
Fecal immunochemical testing with a low hemoglobin threshold for colonoscopy resembled one-time, primary colonoscopy for detecting advanced neoplasias in the first-degree relatives of colorectal...
Increasing dosages of mesalamine by 2.4 g/d for patients with quiescent ulcerative colitis can dramatically reduce concentrations of fecal calprotectin and ultimately decrease the likelihood of...
A mutation in the hepatitis E virus might contribute to ribavirin treatment failure in transplant recipients with chronic HEV infection, according to a small study published in the November issue of...
Topical steroid therapy improved some indicators of mucosal integrity in patients with eosinophilic esophagitis, but proton pump inhibitor therapy did not, according to two studies reported in the...
Patients with inflammatory bowel disease who took thiopurines for at least a year had an almost sixfold greater rate of lymphoma than did the general population, researchers reported in the November...
PHILADELPHIA – In long-term follow-up for the treatment of inflammatory bowel disease, the novel monoclonal antibody vedolizumab continues to remain free of serious infections or other signs of major...
PHILADELPHIA – The first trial conducted in gastroesophageal reflux diseases that employed control of regurgitation as a primary endpoint found a significant advantage for transoral fundoplication...
